Comparison of the Permeability of Metoprolol and Labetalol in Rat, Mouse, and Caco-2 Cells: Use as a Reference Standard for BCS Classification

被引:68
作者
Incecayir, Tuba [1 ,2 ]
Tsume, Yasuhiro [1 ]
Amidon, Gordon L. [1 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] Gazi Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06330 Ankara, Turkey
关键词
Biopharmaceutics Classification Systems (BCS); Caco-2; labetalol; metoprolol; permeability; reference standard; single-pass intestinal perfusion; PREDICTING DRUG DISPOSITION; SITU INTESTINAL PERFUSION; P-GLYCOPROTEIN; BETA-BLOCKERS; IN-VITRO; BIOPHARMACEUTICS CLASSIFICATION; GASTROINTESTINAL-TRACT; KNOCKOUT MICE; HUMAN JEJUNUM; PK(A) VALUES;
D O I
10.1021/mp300410n
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The purpose of this study was to investigate labetalol as a potential high permeability reference standard for the application of Biopharmaceutics Classification Systems (BCS). Permeabilities of labetalol and metoprolol were investigated in animal intestinal perfusion models and Caco-2 cell monolayers. After isolating specific intestinal segments, in situ single-pass intestinal perfusions (SPIP) were performed in rats and mice. The effective permeabilities (P-eff) of labetalol and metoprolol, an FDA standard for the low/high P-eff class boundary, were investigated in two different segments of rat intestine (proximal jejunum and distal ileum) and in the proximal jejunum of mouse. No significant difference was found between P-eff of metoprolol and labetalol in the jejunum and ileum of rat (0.33 +/- 0.11 X 10(-4) vs 0.38 +/- 0.06 X 10(-4) and 0.57 +/- 0.17 X 10(-4) vs 0.64 +/- 0.30 X 10(-4) cm/s, respectively) and in the jejunum of mouse (0.55 +/- 0.05 X 10(-4) vs 0.59 +/- 0.13 X 10(-4) cm/s). However, P-eff of metoprolol and labetalol were 1.7 and 1.6 times higher in the jejunum of mouse, compared to the jejunum of rat, respectively. Metoprolol and labetalol showed segmental-dependent permeability through the rat intestine, with increased P-eff in the distal ileum in comparison to the proximal jejunum. Most significantly, P-eff of labetalol was found to be concentration-dependent. Decreasing concentrations of labetalol in the perfusate resulted in decreased P-eff compared to P-eff of metoprolol. The intestinal epithelial permeability of labetalol was lower than that of metoprolol in Caco-2 cells at both apical pH 6.5 and 7.5 (5.96 +/- 1.96 X 10(-6) VS 9.44 +/- 3.44 X 10(-6) and 15.9 +/- 2.2 X 10(-6) vs 23.2 +/- 7.1 X 10(-6) cm/s, respectively). Labetalol exhibited higher permeability in basolateral to apical (BL-AP) compared to AP-BL direction in Caco-2 cells at 0.1 times the highest dose strength (HDS) (46.7 +/- 6.5 X 10(-6) vs 14.2 +/- 1.5 X 10(-6) cm/s). The P-eff inhibitor, verapamil, significantly increased AP-BL and decreased BL-AP direction transport of labetalol. Overall, labetalol showed high P-eff in rat and mouse intestinal perfusion models similar to metoprolol at a concentration based on HDS. However, the concentration-dependent permeability of labetalol in mice due to P-gp and the inhibition study with verapamil in Caco-2 cells indicated that labetalol is not an ideal reference standard for BCS classification.
引用
收藏
页码:958 / 966
页数:9
相关论文
共 51 条
  • [1] Labetalol absorption kinetics:: Rat small intestine and colon studies
    Abushammala, I.
    Garrigues, T. M.
    Casabo, V. G.
    Nacher, A.
    Martin-Villodre, A.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (08) : 1733 - 1741
  • [2] A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY
    AMIDON, GL
    LENNERNAS, H
    SHAH, VP
    CRISON, JR
    [J]. PHARMACEUTICAL RESEARCH, 1995, 12 (03) : 413 - 420
  • [3] [Anonymous], PRODUCT INFORMATION
  • [4] [Anonymous], DRAFT GUIDANCE ON LA
  • [5] THERMODYNAMICS OF PARTITIONING IN THE N-OCTANOL WATER-SYSTEM OF SOME BETA-BLOCKERS
    BURGOT, G
    SERRAND, P
    BURGOT, JL
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 63 (01) : 73 - 76
  • [6] Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model
    Cao, Xianhua
    Gibbs, Seth T.
    Fang, Lanyan
    Miller, Heather A.
    Landowski, Christopher P.
    Shin, Ho-Chul
    Lennernas, Hans
    Zhong, Yanqiang
    Amidon, Gordon L.
    Yu, Lawrence X.
    Sun, Duxin
    [J]. PHARMACEUTICAL RESEARCH, 2006, 23 (08) : 1675 - 1686
  • [7] Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability
    Cao, Xianhua
    Yu, Lawrence X.
    Barbaciru, Catalin
    Landowski, Christopher P.
    Shin, Ho-Chul
    Gibbs, Seth
    Miller, Heather A.
    Amidon, Gordon L.
    Sun, Duxin
    [J]. MOLECULAR PHARMACEUTICS, 2005, 2 (04) : 329 - 340
  • [8] The BCS, BDDCS, and Regulatory Guidances
    Chen, Mei-Ling
    Amidon, Gordon L.
    Benet, Leslie Z.
    Lennernas, Hans
    Yu, Lawrence X.
    [J]. PHARMACEUTICAL RESEARCH, 2011, 28 (07) : 1774 - 1778
  • [9] Application of the biopharmaceutical classification system in clinical drug development - An industrial view
    Cook, Jack
    Addicks, William
    Wu, Yunhui Henry
    [J]. AAPS JOURNAL, 2008, 10 (02) : 306 - 310
  • [10] Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption
    Custodio, Joseph M.
    Wu, Chi-Yuan
    Benet, Leslie Z.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (06) : 717 - 733